Claims
- 1. An expression vector comprising a nucleic acid encoding the polypeptide set forth in SEQ ID NO: 5.
- 2. A host cell comprising the expression vector of claim 1.
- 3. An expression vector comprising the polynucleotide set forth in SEQ ID NO: 10.
- 4. A host cell comprising the expression vector of claim 3.
- 5-26. (canceled).
- 27. An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 10 or a degenerate variant of SEQ ID NO: 10.
- 28. An isolated nucleic acid molecule comprising a sequence that encodes a polypeptide having amino acid sequence SEQ ID NO: 5, or SEQ ID NO: 5 with conservative amino acid substitutions.
- 29. A method of preparing a protein having amino acid sequence SEQ ID NO:5, or SEQ ID NO: 5 with conservative amino acid substitutions comprising culturing the host cell of claim 2 under conditions permitting the expression of said protein and recovering said protein from the cell culture.
- 30-57. (canceled).
- 58. An immunogenic composition capable of stimulating an immune response in an animal to enteroaggregative E. coli comprising a pharmaceutically acceptable carrier and one or more isolated nucleic acid molecules which encode a polypeptide selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8, or these sequences with conservative amino acid substitutions.
- 59. The immunogenic composition of claim 58, wherein said immunogenic composition is administered by a route selected from the group consisting of oral administration, nasal administration, inhalation, ophthalmic administration, rectal administration and vaginal administration.
- 60-61. (canceled).
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This non-provisional application claims priority under 35 U.S.C. §120 to provisional applications U.S. Ser. Nos. 60/334,425 and 60/398,775, filed Nov. 30, 2001 and Jul. 26, 2002, respectively, the contents of which are incorporated herein by reference in their entirety.
STATEMENT OF GOVERNMENTAL INTEREST
[0002] This invention was made with U.S. Government support under NIADA grant No. AI33096 awarded by the National Institutes of Health. The U.S. Government may have certain rights in this invention.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60334425 |
Nov 2001 |
US |
|
60398775 |
Jul 2002 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
10307294 |
Dec 2002 |
US |
Child |
10847391 |
May 2004 |
US |